Cyclophosphamide for the treatment of progressive low-grade astrocytoma: A Pediatric Oncology Group Phase II study

Richard P. Kadota; Larry E. Kun; James W. Langston; Peter C. Burger; Michael E. Cohen; Donald H. Mahoney; Andrew W. Walter; John H. Rodman; Andrew Parent; Edward Buckley; James L. Kepner; Henry S. Friedman

doi:10.1097/00043426-199905000-00007

Cyclophosphamide for the treatment of progressive low-grade astrocytoma: A Pediatric Oncology Group Phase II study

Richard P. Kadota, Larry E. Kun, James W. Langston, Peter C. Burger, Michael E. Cohen, Donald H. Mahoney, Andrew W. Walter, John H. Rodman, Andrew Parent, Edward Buckley, James L. Kepner, Henry S. Friedman

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Purpose: Results of a phase II trial of cyclophosphamide (CPM) for children with progressive low-grade astrocytoma are reported. Patients and Methods: Fifteen patients with a median age of 39 months (range, 2 to 71) were included in this study. The tumors of 11 children were located in the optic pathway, hypothalamus, or thalamus. Four courses of intravenous CPM 1.2 g/m² were administered every 3 weeks during the upfront window portion of this protocol. Subsequently, chemotherapy was to continue with CPM, vincristine, and carboplatin for 2 years. Results: By study design, the first 14 patients were centrally reviewed after completion of the initial 4 CPM courses. Toxicity was primarily hematologic. One patients had a complete response, 8 had stable disease, and 5 had progressive disease (PD). The excessive number of children with PD prompted study closure. Conclusion: CPM as used in this protocol showed insufficient activity against astrocytoma to justify further patient accrual.

Original language	English (US)
Pages (from-to)	198-202
Number of pages	5
Journal	Journal of Pediatric Hematology/Oncology
Volume	21
Issue number	3
DOIs	https://doi.org/10.1097/00043426-199905000-00007
State	Published - May 1 1999

Keywords

Astrocytoma
Cyclophosphamide
Optic glioma
Pediatric brain tumor
Phase II study

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1097/00043426-199905000-00007

Cite this

Kadota, R. P., Kun, L. E., Langston, J. W., Burger, P. C., Cohen, M. E., Mahoney, D. H., Walter, A. W., Rodman, J. H., Parent, A., Buckley, E., Kepner, J. L., & Friedman, H. S. (1999). Cyclophosphamide for the treatment of progressive low-grade astrocytoma: A Pediatric Oncology Group Phase II study. Journal of Pediatric Hematology/Oncology, 21(3), 198-202. https://doi.org/10.1097/00043426-199905000-00007

Kadota, RP, Kun, LE, Langston, JW, Burger, PC, Cohen, ME, Mahoney, DH, Walter, AW, Rodman, JH, Parent, A, Buckley, E, Kepner, JL & Friedman, HS 1999, 'Cyclophosphamide for the treatment of progressive low-grade astrocytoma: A Pediatric Oncology Group Phase II study', Journal of Pediatric Hematology/Oncology, vol. 21, no. 3, pp. 198-202. https://doi.org/10.1097/00043426-199905000-00007

@article{9193ed21c6ab4e8b9249e7da8400eb46,

title = "Cyclophosphamide for the treatment of progressive low-grade astrocytoma: A Pediatric Oncology Group Phase II study",

abstract = "Purpose: Results of a phase II trial of cyclophosphamide (CPM) for children with progressive low-grade astrocytoma are reported. Patients and Methods: Fifteen patients with a median age of 39 months (range, 2 to 71) were included in this study. The tumors of 11 children were located in the optic pathway, hypothalamus, or thalamus. Four courses of intravenous CPM 1.2 g/m2 were administered every 3 weeks during the upfront window portion of this protocol. Subsequently, chemotherapy was to continue with CPM, vincristine, and carboplatin for 2 years. Results: By study design, the first 14 patients were centrally reviewed after completion of the initial 4 CPM courses. Toxicity was primarily hematologic. One patients had a complete response, 8 had stable disease, and 5 had progressive disease (PD). The excessive number of children with PD prompted study closure. Conclusion: CPM as used in this protocol showed insufficient activity against astrocytoma to justify further patient accrual.",

keywords = "Astrocytoma, Cyclophosphamide, Optic glioma, Pediatric brain tumor, Phase II study",

author = "Kadota, {Richard P.} and Kun, {Larry E.} and Langston, {James W.} and Burger, {Peter C.} and Cohen, {Michael E.} and Mahoney, {Donald H.} and Walter, {Andrew W.} and Rodman, {John H.} and Andrew Parent and Edward Buckley and Kepner, {James L.} and Friedman, {Henry S.}",

year = "1999",

month = may,

day = "1",

doi = "10.1097/00043426-199905000-00007",

language = "English (US)",

volume = "21",

pages = "198--202",

journal = "Journal of Pediatric Hematology/Oncology",

issn = "1077-4114",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Cyclophosphamide for the treatment of progressive low-grade astrocytoma

T2 - A Pediatric Oncology Group Phase II study

AU - Kadota, Richard P.

AU - Kun, Larry E.

AU - Langston, James W.

AU - Burger, Peter C.

AU - Cohen, Michael E.

AU - Mahoney, Donald H.

AU - Walter, Andrew W.

AU - Rodman, John H.

AU - Parent, Andrew

AU - Buckley, Edward

AU - Kepner, James L.

AU - Friedman, Henry S.

PY - 1999/5/1

Y1 - 1999/5/1

N2 - Purpose: Results of a phase II trial of cyclophosphamide (CPM) for children with progressive low-grade astrocytoma are reported. Patients and Methods: Fifteen patients with a median age of 39 months (range, 2 to 71) were included in this study. The tumors of 11 children were located in the optic pathway, hypothalamus, or thalamus. Four courses of intravenous CPM 1.2 g/m2 were administered every 3 weeks during the upfront window portion of this protocol. Subsequently, chemotherapy was to continue with CPM, vincristine, and carboplatin for 2 years. Results: By study design, the first 14 patients were centrally reviewed after completion of the initial 4 CPM courses. Toxicity was primarily hematologic. One patients had a complete response, 8 had stable disease, and 5 had progressive disease (PD). The excessive number of children with PD prompted study closure. Conclusion: CPM as used in this protocol showed insufficient activity against astrocytoma to justify further patient accrual.

AB - Purpose: Results of a phase II trial of cyclophosphamide (CPM) for children with progressive low-grade astrocytoma are reported. Patients and Methods: Fifteen patients with a median age of 39 months (range, 2 to 71) were included in this study. The tumors of 11 children were located in the optic pathway, hypothalamus, or thalamus. Four courses of intravenous CPM 1.2 g/m2 were administered every 3 weeks during the upfront window portion of this protocol. Subsequently, chemotherapy was to continue with CPM, vincristine, and carboplatin for 2 years. Results: By study design, the first 14 patients were centrally reviewed after completion of the initial 4 CPM courses. Toxicity was primarily hematologic. One patients had a complete response, 8 had stable disease, and 5 had progressive disease (PD). The excessive number of children with PD prompted study closure. Conclusion: CPM as used in this protocol showed insufficient activity against astrocytoma to justify further patient accrual.

KW - Astrocytoma

KW - Cyclophosphamide

KW - Optic glioma

KW - Pediatric brain tumor

KW - Phase II study

UR - http://www.scopus.com/inward/record.url?scp=17144472486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144472486&partnerID=8YFLogxK

U2 - 10.1097/00043426-199905000-00007

DO - 10.1097/00043426-199905000-00007

M3 - Article

C2 - 10363852

AN - SCOPUS:17144472486

SN - 1077-4114

VL - 21

SP - 198

EP - 202

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

IS - 3

ER -

Cyclophosphamide for the treatment of progressive low-grade astrocytoma: A Pediatric Oncology Group Phase II study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this